Introduction
History of extracorporeal organ support
Renal replacement | CO2 Removal | Extracorporeal oxygenation | |
---|---|---|---|
Extracorporeal blood flow (mL/min) | 200–300 | 500–1000 | 2000–4000 |
Blood pumping | Optional | Optional | Required |
Hemodynamic changes | Small | Small | Major |
Vascular access | Small | Intermediate | Large |
Requirement for anticoagulation | Small | Small | Large |
Risk | Complication | |
---|---|---|
Extracorporeal circuit | Volume loss | Hypovolemia; anemia |
Blood flow | Hemodynamic impairment | |
Biocompatibility | Allergy, inflammation, immune modulation | |
Anticoagulation | Bleeding | |
Thermal loss | Hypothermia | |
Vascular access | Vascular damage | Bleeding |
Thrombosis | Venous and arterial embolism | |
Blood stream infection | Sepsis |
Characteristics of specific organ support
Renal replacement
-
Slow continuous ultrafiltration (SCUF) is a continuous therapy that might be used to reach a correction of fluid overload in refractory patients by applying a slow removal of plasma water.
-
Continuous veno-venous hemofiltration (CVVH) provides solute clearance and volume control by convection. Replacement fluids are infused before or after the hemofilter to replace the ultrafiltrate by predilution or postdilution, respectively.
-
Continuous veno-venous hemodialysis (CVVHD) uses diffusion for detoxification. This is achieved flowing dialysate into the dialysate compartment of the hemodialyzer either co-currently or counter-currently. IHD refers to intermittent hemodialysis.
-
Continuous veno-venous hemodiafiltration (CVVHDF) is a combination of the two previous techniques. The intermittent variant is known as intermittent hemodiafiltration (IHDF),
-
Continuous veno-venous high-flux hemodialysis (CVVHFD) or intermittent high-flux dialysis (IHFD) is a modified hemodialysis where high-flux membranes are applied.
Extracorporeal lung support: oxygenation
Extracorporeal lung support: CO2 removal
Reference | Device | Number | Main inclusion/exclusion criteria | Additional organ failures | Blood flow; catheter | Period of ECCO2R |
---|---|---|---|---|---|---|
Terragni et al. [28] | Decap | 10; 22 controls | ARDS (AECC) ≤3 days | SAPS II ca. 48 | 300–350 mL/min 14 Fr | >72 h |
Fanelli et al.[29] | A‑Lung | 15 | Moderate ARDS (P/F 100–200 mm Hg) | SOFA 10 ± 4 | 300–350 mL/min 15.5 Fr | 3 days |
Schmidt et al. [30] | PrismaLung | 20 | Mild to moderate ARDS (P/F 100–300 mm Hg) | SAPS 56 ± 21 SOFA 9 ± 4 | 420 mL/min 13 Fr | ≥1 day (mean 31 h) |
Combes et al. [17] | 33 A-Lung 34 iLAactivve 28 Cardiohelp | 95 | Moderate ARDS (P/F 100–200 mm Hg) | SAPS 46 ± 16 SOFA 7 ± 3 | 300–500 mL/min (A-Lung) 800–1000 (iLAactivve; CardoHelp) | ≥1 day |
Jugular twin-catheter 15.5 Fr (A-Lung) 18.20 Fr (iLA; CardioHelp) | ||||||
Nentwich et al. [31] | PrismaLung | 20 | Hypercapnic acidosis with a pH below 7.30 and a PaCO2 of at least 55 mm Hg under a plateau pressure of at least 25 cmH2O | SOFA 14 (8–18) | Target flow 400 mL/h 13.5 Fr | 3 days |
ADVOPROTECT (ongoing; Huber et al.) | ADVOS multi | 20 | Moderate or severe ARDS (P/F ≤200 mm Hg) | No restrictions. At least kidney or liver failure | Target flow 200 mL/h 13 Fr | ≥1 day |
Extracorporeal liver support
Advanced organ support
Liver support | Renal support | ECCO2R | Acid–base modulation | Improved coagulation | Resources required | Availability | Financial burden | |
---|---|---|---|---|---|---|---|---|
SPAD | + | + | − | − | − | +++ | ++ | +++ |
MARS | + | + | − | − | − | +++ | + | +++ |
PROMETHEUS | + | + | − | − | − | +++ | + | +++ |
ADVOS | + | + | + | + | − | ++ | + | +++ |
ELAD | + | + | − | − | − | ++++ | − | ++++ |
Plasma separation | + | − | − | − | + | ++ | ++ | ++ |
CytoSorb | + | − | − | − | − | ++ | +++ | ++ |
Detoxification in sepsis
Modular or integrated multiorgan support?
Combination of single organ support devices | Multiorgan support devices | ||
---|---|---|---|
Advantage | Disadvantage | Advantage | Disadvantage |
Step-wise combination | Large extracorporeal volume | Limitation of extracorporeal volume | Not yet generally available |
Use of familiar technique | Personal resources for assembling several devices | Limitation of personal resources | Little clinical data available |
Cumulative costs of several devices | Additional features: modulation of acid–base balance | ||
Lack of “match-up” |